Ürotelyal Karsinomlar Ve Çevre Non Tümöral Mukozalarında Cd133, Cd44, Cox-2'nin İmmunhistokimyasal Analizi Ve Non Tümöral Mukozaların Malignite Potansiyelinin Belirlenmesi
Yükleniyor...
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Mesane kanseri dünyada en sık görülen 10. kanser türü olup kansere bağlı ölümler arasında 13. sırada yer almaktadır. Yüksek nüks riski mevcudiyeti dolayısıyla ve yaşam boyu takip gerektimesi diğer tümörlere nazaran tedavi maliyetlerini artırmaktadır. Son zamanlarda kanser kök hücreleri ile yapılan çalışmalar kök hücrelerin prognoz, nüks ve tedaviye cevapta kuvvetli ilişkinin olduğunu göstermiştir. Organizmada kanser kök hücrelerine dönüşüm, doku rejenerasyonu esnasında, toksinlere, enfeksiyonlara, radyasyona veya mutasyonlara neden olan metabolik etkilere cevap olarak başlayabilir veya hızlanabilir. CD133, CD44 kanser kök hücreleri içerisinde tanımlanan önemli belirteçlerdir. COX-2 inflamasyonla PGE2 aracılı kök hücrelerini aktive edebilir. Çalışmamızda Meram Tıp Fakültesi Patoloji Anabilim Dalında ürotelyal karsinom (ÜK) ve kronik sistit (KS) tanısı almış olgular yeniden değerlendirildi. Olgulara immünhistokimyasal olarak CD133, CD44, COX-2 boyaları uygulandı. Elde edilen veriler klinikopatolojik parametrelerle istatiksel olarak karşılaştırıldı. CD133 boyaması ile papiller ürotelyal karsinom (PÜK) olgularında tümör içermeyen komşu mukozada, tümör alanına göre istatiksel olarak anlamlı pozitif ekspresyon saptandı (p=0,020). 60 yaş ve üzeri olguların tümöral alanlarında CD133 negatif ekspresyon oranı 60 yaşın altındaki olgulara göre istatiksel olarak anlamlı düzeyde yüksek saptandı (p=0,021). Yüksek dereceli tümörlerde CD133 boyanma şiddetinin güçlü olması istatiksel olarak anlamlı yüksek bulundu (p=0,028). CD44 ile PÜK ve KÜK olgularında tümör içermeyen komşu mukozalarda, tümöral alana göre istatiksel olarak anlamlı pozitif ekspresyon saptandı (p<0,001, p=0,037). Yüksek dereceli tümörlerde ve lenf nodu metastazı olan olgularda CD44 boyanma şiddetinin güçlü olması istatiksel olarak anlamlı yüksek bulundu (p=0,035, p=0,015). Kronik sistit tanılı olgularda ise ürotelyal karsinomların normal komşu mukozalarına göre COX-2 boyanma şiddeti ve nihai ekspresyonu istatistiksel olarak anlamlı düzeyde yüksek idi (p=0,003). PÜK tanılı olguların normal mukozalarında COX-2 ekspresyon oranı KÜK tanılı olguların tümör içermeyen mukozaları ve kronik sistit tanılı olgulara göre istatistiksel olarak anlamlı olarak düşük saptandı (p<0,001). KÜK tanılı
v
olguların tümöral alanında PÜK olgularının tümöral alanına göre COX-2 boyana şiddetinin güçlü olması istatistiksel olarak anlamlı bulundu (p=0,028). Yüksek dereceli tümörlerde COX-2 boyanma şiddetinin güçlü olması istatiksel olarak anlamlı yüksek bulundu (p= 0,027). Bütün bu veriler eşliğinde CD133, CD44, COX-2 moleküllerinin kötü prognozla ilişkili olabileceğini düşünmekteyiz.
Bladder cancer is the 10th most common cancer in the world and is the 13th among cancer-related deaths. Due to the high risk of recurrence and the need for lifelong follow-up, treatment costs increase compared to other tumors. Recent studies with cancer stem cells have shown that stem cells have a strong relationship with prognosis, recurrence and response to treatment. Transformation into cancer stem cells in the organism may begin or accelerate during tissue regeneration in response to toxins, infections, radiation or metabolic effects that cause mutations. CD133 and CD44 are important markers identified in the subpopulation of cancer stem cells. COX-2 can activate PGE- 2 mediated stem cells with inflammation. In our study, cases diagnosed with UC and CS in the Pathology Department of Meram Faculty of Medicine were evaluated. Immunohistochemical CD133, CD44, COX-2 stains were applied to the cases and the data were statistically compared with clinicopathological parameters. Statistically significant positive expression was found in the adjacent mucosa without tumor in CD133 and PUC cases compared to the tumor (p=0.020). CD133 negative expression rate in tumoral areas of patients aged 60 years and older was found to be statistically significantly higher than those under 60 years of age (p=0.021). The strength of CD133 staining in high-grade tumors was found to be statistically significantly higher (p=0.028). Statistically significant positive expression was found in the adjacent mucosa without tumor in CD44 and PUC and CUC cases (p<0.001, p=0.037). In high-grade tumors and in cases with lymph node metastasis, the intensity of CD44 staining was found to be statistically significantly higher (p=0.035, p=0.015). In cases with chronic cystitis, the intensity and final expression of COX-2 staining were found to be statistically significantly higher than the normal adjacent mucosa of urothelial carcinomas (p=0.003). The rate of COX-2 expression in the normal mucosa of patients with PUC was found to be statistically significantly lower than the mucosa of patients with CUC without tumor and those with chronic cystitis (p<0.001). The strong expression of COX-2 was found to be statistically vii significantly higher in the tumoral area of the patients with CUC compared to the tumoral area of the PUC patients (p=0.028). We found that the intensity of COX-2 staining was strong in high-grade tumors and statistically significantly higher (p= 0.027). We think that CD133, CD44, COX-2 molecules may be associated with poor prognosis.
Bladder cancer is the 10th most common cancer in the world and is the 13th among cancer-related deaths. Due to the high risk of recurrence and the need for lifelong follow-up, treatment costs increase compared to other tumors. Recent studies with cancer stem cells have shown that stem cells have a strong relationship with prognosis, recurrence and response to treatment. Transformation into cancer stem cells in the organism may begin or accelerate during tissue regeneration in response to toxins, infections, radiation or metabolic effects that cause mutations. CD133 and CD44 are important markers identified in the subpopulation of cancer stem cells. COX-2 can activate PGE- 2 mediated stem cells with inflammation. In our study, cases diagnosed with UC and CS in the Pathology Department of Meram Faculty of Medicine were evaluated. Immunohistochemical CD133, CD44, COX-2 stains were applied to the cases and the data were statistically compared with clinicopathological parameters. Statistically significant positive expression was found in the adjacent mucosa without tumor in CD133 and PUC cases compared to the tumor (p=0.020). CD133 negative expression rate in tumoral areas of patients aged 60 years and older was found to be statistically significantly higher than those under 60 years of age (p=0.021). The strength of CD133 staining in high-grade tumors was found to be statistically significantly higher (p=0.028). Statistically significant positive expression was found in the adjacent mucosa without tumor in CD44 and PUC and CUC cases (p<0.001, p=0.037). In high-grade tumors and in cases with lymph node metastasis, the intensity of CD44 staining was found to be statistically significantly higher (p=0.035, p=0.015). In cases with chronic cystitis, the intensity and final expression of COX-2 staining were found to be statistically significantly higher than the normal adjacent mucosa of urothelial carcinomas (p=0.003). The rate of COX-2 expression in the normal mucosa of patients with PUC was found to be statistically significantly lower than the mucosa of patients with CUC without tumor and those with chronic cystitis (p<0.001). The strong expression of COX-2 was found to be statistically vii significantly higher in the tumoral area of the patients with CUC compared to the tumoral area of the PUC patients (p=0.028). We found that the intensity of COX-2 staining was strong in high-grade tumors and statistically significantly higher (p= 0.027). We think that CD133, CD44, COX-2 molecules may be associated with poor prognosis.
Açıklama
Anahtar Kelimeler
Cancer stem cell, CD133, CD44, COX-2, Urothelial Carcinoma, Urothelial Mucosa, Cancer stem cell, CD133, CD44, COX-2, Urothelial Carcinoma, Urothelial Mucosa
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Karakaya. H. B. (2023). Ürotelyal Karsinomlar Ve Çevre Non Tümöral Mukozalarında Cd133, Cd44, Cox-2'nin İmmunhistokimyasal Analizi Ve Non Tümöral Mukozaların Malignite Potansiyelinin Belirlenmesii. (Yayınlanmamış tıpta uzmanlık tezi) Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi Cerrahi Tıp Bilimleri Bölümü Tıbbi Patoloji Anabilim Dalı, Konya.
